Shares of MiMedx Group (NASDAQ:MDXG), a biopharmaceutical company focused on regenerative medicine, were down 11% as of 3:15 p.m. EST on Friday.
The drop was spurred by an article published on Thursday stating that the company had failed to make legally required reports of payments that it made to doctors.
The article published by The Wall Street Journal stated that MiMedx had not disclosed its financial relationships with more than 20 doctors — a failure to comply with the Physician Payments Sunshine Act, which was passed in 2013.
To read the article by Brian Feroldi
